On 14 October 2016, orphan designation (EU/3/16/1752) was granted by the European Commission to Pfizer Limited, United Kingdom, for human monoclonal IgG1 antibody against tissue factor pathway (also known as PF-06741086) for the treatment of haemophilia A.
The sponsorship was transferred to Pfizer Europe MA EEIG, Belgium, in November 2018.
Human monoclonal IgG1 antibody against tissue factor pathway inhibitor
Treatment of haemophilia A
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: